Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Lenz Therapeutics Inc's Business Segments
Lenz Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 2
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 2 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product86.8%
- License13.2%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 2 | 86.8% |
| License | $ 0 | 13.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue by Product & Service Category -
- License26.2%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License | $ 5 | 26.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Lenz Therapeutics Inc
The company is a commercial pharmaceutical firm focused on developing and commercializing therapies to improve vision. Its principal product is VIZZ® (aceclidine ophthalmic solution) 1.44%, the first FDA-approved aceclidine-based eye drop for treating presbyopia, a condition affecting approximately 1.8 billion people worldwide and 128 million in the U.S. VIZZ is a once-daily eye drop designed to restore clear near vision for up to 10 hours without the need for reading glasses. It operates as a predominantly pupil-selective miotic that contracts the iris sphincter muscle, creating a pinhole effect to extend depth of focus and improve near vision without causing a myopic shift. The company commercially launched VIZZ in the U.S. in August 2025, initially targeting eye care professionals, with product availability expanded to retail pharmacies by November 2025. It is also establishing licensing and distribution partnerships internationally to provide global access to VIZZ. The company estimates the U.S. market opportunity for VIZZ to exceed $3 billion and has assembled an executive team to lead in this market category.